Pyxis Oncology Inc
NASDAQ:PYXS

Watchlist Manager
Pyxis Oncology Inc Logo
Pyxis Oncology Inc
NASDAQ:PYXS
Watchlist
Price: 1.21 USD 0.83% Market Closed
Market Cap: 75m USD
Section:
Wall Street Price Targets
Wall Street Price Targets
Revenue Forecast
Operating Income Forecast
Net Income Forecast
See Also
Price Target
Average
+11%
Revenue
Forecast
+6%
Operating Income
Forecast
+15%
Net Income
Forecast
+10%

Wall Street
Price Targets

PYXS Price Targets Summary
Pyxis Oncology Inc

Wall Street analysts forecast PYXS stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for PYXS is 6.32 USD with a low forecast of 5.05 USD and a high forecast of 8.4 USD.

PYXS Lowest Forecast
Wall Street Target
5.05 USD
317% Upside
PYXS Average Forecast
Wall Street Target
6.32 USD
423% Upside
PYXS Highest Forecast
Wall Street Target
8.4 USD
594% Upside
Lowest
Price Target
5.05 USD
317% Upside
Average
Price Target
6.32 USD
423% Upside
Highest
Price Target
8.4 USD
594% Upside
Pyxis Oncology Inc Competitors:
Price Targets
RYTM
Rhythm Pharmaceuticals Inc
36% Upside
BIIB
Biogen Inc
32% Upside
KALV
Kalvista Pharmaceuticals Inc
113% Upside
ABBV
Abbvie Inc
14% Upside
RYTM
Rhythm Pharmaceuticals Inc
36% Upside
BIIB
Biogen Inc
32% Upside
KALV
Kalvista Pharmaceuticals Inc
113% Upside
ABBV
Abbvie Inc
14% Upside
IKT
Inhibikase Therapeutics Inc
321% Upside
IMNM
Immunome Inc
162% Upside
F
FLUO
Fluoguide AS
172% Upside
MDXG
MiMedx Group Inc
104% Upside

Revenue
Forecast

Revenue Estimate
Pyxis Oncology Inc

The compound annual growth rate of Pyxis Oncology Inc's revenue for the next 3 years is -22%.

N/A
Past Growth
-22%
Estimated Growth
N/A
Estimates Accuracy
N/A
Average
What are analyst estimates?

Operating Income
Forecast

Operating Income Estimate
Pyxis Oncology Inc

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-4%
Average Miss
What are analyst estimates?

Net Income
Forecast

Net Income Estimate
Pyxis Oncology Inc

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-44%
Average Miss
What are analyst estimates?

See Also

Summary
PYXS intrinsic value, competitors valuation, and company profile.
DCF Valuation
PYXS stock valuation using Discount Cash Flow valuation method.
Relative Valuation
PYXS stock valuation using valuation multiples.
Wall Street Estimates
PYXS price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
PYXS stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is PYXS's stock price target?
Price Target
6.32 USD

According to Wall Street analysts, the average 1-year price target for PYXS is 6.32 USD with a low forecast of 5.05 USD and a high forecast of 8.4 USD.

What is Pyxis Oncology Inc's Revenue forecast?
Projected CAGR
-22%

The compound annual growth rate of Pyxis Oncology Inc's revenue for the next 3 years is -22%.

Back to Top
ALPHA SPREAD
Follow us
Join more than 262,100+ value investors using Alpha Spread
Create Free Account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.